163 related articles for article (PubMed ID: 34676684)
1. β3 adrenergic receptor as potential therapeutic target in ADPKD.
Schena G; Carmosino M; Chiurlia S; Onuchic L; Mastropasqua M; Maiorano E; Schena FP; Caplan MJ
Physiol Rep; 2021 Oct; 9(20):e15058. PubMed ID: 34676684
[TBL] [Abstract][Full Text] [Related]
2. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells.
Belibi FA; Reif G; Wallace DP; Yamaguchi T; Olsen L; Li H; Helmkamp GM; Grantham JJ
Kidney Int; 2004 Sep; 66(3):964-73. PubMed ID: 15327388
[TBL] [Abstract][Full Text] [Related]
3. The tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease.
Jamadar A; Suma SM; Mathew S; Fields TA; Wallace DP; Calvet JP; Rao R
Cell Death Dis; 2021 Oct; 12(10):947. PubMed ID: 34650051
[TBL] [Abstract][Full Text] [Related]
4. β3 adrenergic receptor in the kidney may be a new player in sympathetic regulation of renal function.
Procino G; Carmosino M; Milano S; Dal Monte M; Schena G; Mastrodonato M; Gerbino A; Bagnoli P; Svelto M
Kidney Int; 2016 Sep; 90(3):555-67. PubMed ID: 27206969
[TBL] [Abstract][Full Text] [Related]
5. Endogenous concentrations of ouabain act as a cofactor to stimulate fluid secretion and cyst growth of in vitro ADPKD models via cAMP and EGFR-Src-MEK pathways.
Jansson K; Nguyen AN; Magenheimer BS; Reif GA; Aramadhaka LR; Bello-Reuss E; Wallace DP; Calvet JP; Blanco G
Am J Physiol Renal Physiol; 2012 Oct; 303(7):F982-90. PubMed ID: 22859406
[TBL] [Abstract][Full Text] [Related]
6. Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model.
Pastor-Soler NM; Li H; Pham J; Rivera D; Ho PY; Mancino V; Saitta B; Hallows KR
Am J Physiol Renal Physiol; 2022 Jan; 322(1):F27-F41. PubMed ID: 34806449
[TBL] [Abstract][Full Text] [Related]
7. A potential strategy for reducing cysts in autosomal dominant polycystic kidney disease with a CFTR corrector.
Yanda MK; Liu Q; Cebotaru L
J Biol Chem; 2018 Jul; 293(29):11513-11526. PubMed ID: 29875161
[TBL] [Abstract][Full Text] [Related]
8. STAT5 drives abnormal proliferation in autosomal dominant polycystic kidney disease.
Fragiadaki M; Lannoy M; Themanns M; Maurer B; Leonhard WN; Peters DJ; Moriggl R; Ong AC
Kidney Int; 2017 Mar; 91(3):575-586. PubMed ID: 28104302
[TBL] [Abstract][Full Text] [Related]
9. Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease.
Wang X; Harris PC; Somlo S; Batlle D; Torres VE
Nephrol Dial Transplant; 2009 Feb; 24(2):526-34. PubMed ID: 18826972
[TBL] [Abstract][Full Text] [Related]
10. Strategies to inhibit cyst formation in ADPKD.
Calvet JP
Clin J Am Soc Nephrol; 2008 Jul; 3(4):1205-11. PubMed ID: 18434615
[TBL] [Abstract][Full Text] [Related]
11. Calmodulin-sensitive adenylyl cyclases mediate AVP-dependent cAMP production and Cl- secretion by human autosomal dominant polycystic kidney cells.
Pinto CS; Reif GA; Nivens E; White C; Wallace DP
Am J Physiol Renal Physiol; 2012 Nov; 303(10):F1412-24. PubMed ID: 22952279
[TBL] [Abstract][Full Text] [Related]
12. EP2 receptor mediates PGE2-induced cystogenesis of human renal epithelial cells.
Elberg G; Elberg D; Lewis TV; Guruswamy S; Chen L; Logan CJ; Chan MD; Turman MA
Am J Physiol Renal Physiol; 2007 Nov; 293(5):F1622-32. PubMed ID: 17728378
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease.
Cebotaru L; Liu Q; Yanda MK; Boinot C; Outeda P; Huso DL; Watnick T; Guggino WB; Cebotaru V
Kidney Int; 2016 Jul; 90(1):90-9. PubMed ID: 27165822
[TBL] [Abstract][Full Text] [Related]
14. Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease.
Devuyst O; Torres VE
Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):459-70. PubMed ID: 23736843
[TBL] [Abstract][Full Text] [Related]
15. [Inhibitors of intra-cystic secretion: novel therapies in ADPKD (Autosomal Dominant Polycystic Kidney Disease)].
Miranda N; Miranda F; Rinaldi L; Stratigis S; Capasso G
G Ital Nefrol; 2013; 30(1):. PubMed ID: 23832438
[TBL] [Abstract][Full Text] [Related]
16. Double inhibition of cAMP and mTOR signalling may potentiate the reduction of cell growth in ADPKD cells.
de Stephanis L; Bonon A; Varani K; Lanza G; Gafà R; Pinton P; Pema M; Somlo S; Boletta A; Aguiari G
Clin Exp Nephrol; 2017 Apr; 21(2):203-211. PubMed ID: 27278932
[TBL] [Abstract][Full Text] [Related]
17. Periostin induces proliferation of human autosomal dominant polycystic kidney cells through alphaV-integrin receptor.
Wallace DP; Quante MT; Reif GA; Nivens E; Ahmed F; Hempson SJ; Blanco G; Yamaguchi T
Am J Physiol Renal Physiol; 2008 Nov; 295(5):F1463-71. PubMed ID: 18753297
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial Abnormality Facilitates Cyst Formation in Autosomal Dominant Polycystic Kidney Disease.
Ishimoto Y; Inagi R; Yoshihara D; Kugita M; Nagao S; Shimizu A; Takeda N; Wake M; Honda K; Zhou J; Nangaku M
Mol Cell Biol; 2017 Dec; 37(24):. PubMed ID: 28993480
[TBL] [Abstract][Full Text] [Related]
19. β3-Adrenoreceptor Blockade Reduces Hypoxic Myeloid Leukemic Cells Survival and Chemoresistance.
Calvani M; Dabraio A; Bruno G; De Gregorio V; Coronnello M; Bogani C; Ciullini S; Marca G; Vignoli M; Chiarugi P; Nardi M; Vannucchi AM; Filippi L; Favre C
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32545695
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting Focal Adhesion Kinase Ameliorates Cyst Development in Polycystin-1-Deficient Polycystic Kidney Disease in Animal Model.
He J; Zhang S; Qiu Z; Li X; Huang H; Jin W; Xu Y; Shao G; Wang L; Meng J; Wang S; Geng X; Jia Y; Li M; Yang B; Jenny Lu HA; Zhou H
J Am Soc Nephrol; 2021 Sep; 32(9):2159-2174. PubMed ID: 34465607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
